Elevation Oncology reports data from Phase I trial of EO-3021 for solid tumours

Elevation Oncology has released initial data from the dose escalation section of the ongoing Phase I study of EO-3021, which is targeting patients with advanced solid tumours likely to express Claudin 18.2.